<DOC>
	<DOCNO>NCT02071121</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single dos BIIB061 administer healthy adult volunteer . Secondary objective study population determine single-dose pharmacokinetic ( PK ) profile absolute bioavailability ( Fabs ) BIIB061 determine effect food intake ( high-fat , high-calorie meal ) BIIB061 PK safety .</brief_summary>
	<brief_title>Single Ascending Dose Study Safety , Tolerability , Pharmacokinetics BIIB061 Healthy Adult Volunteers Including Absolute Bioavailability Food Effect</brief_title>
	<detailed_description />
	<criteria>Key Males postmenopausal ( defined menses 12 month confirm folliclestimulating hormone ( FSH ) level determine screen postmenopausal range ) surgically sterile female . All male must practice effective contraception study willing able continue male contraception 3 month dose study treatment . All male participant must also willing refrain sperm donation least 3 month last dose study treatment . Note : Females childbearing potential , allow enter study . Must good health normal vital sign determine Investigator . Participants agree abstain alcohol ingestion duration time study . Must nonsmoker must use chew tobacco nicotine product , least 3 month prior Day 1 . Must body mass index ( BMI ) 18 30 kg/m2 , inclusive . Key History positive test result screen human immunodeficiency virus ( HIV ) . History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , oncologic , major disease , determine Investigator . Clinically significant ( determined Investigator ) 12lead electrocardiogram ( ECG ) abnormality , include correct QT interval use Fridericia 's correction method &gt; 450 m male &gt; 470 m female . History severe allergic anaphylactic reaction . Serious infection ( e.g. , pneumonia , septicemia ) determine Investigator , within 3 month prior Day 1 . Consumption grapefruit grapefruitcontaining product within 3 day dose . Treatment overthecounter product , include herbal and/or alternative health preparation procedure within 14 day prior Day 1 . Current enrollment drug , biologic , device , clinical study , treatment investigational drug approve therapy investigational use within 30 day ( 5 halflives , whichever long ) prior Day 1 . Blood donation ( 1 unit ) within 30 day prior Day 1 History drug alcohol abuse ( determine Investigator ) , positive urine drug/alcohol test , positive cotinine test Screening Day 1 , alcohol use within 48 hour ( report subject ) prior Day 1 . Vigorous exercise ( determined Investigator ) within 48 hour prior Day 1 . History malignant disease , include solid tumor hematologic malignancy . Surgery within 3 month prior Day1 . History seizures childhood febrile seizure . Inability unwillingness comply study requirement . NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>BIIB061</keyword>
	<keyword>Healthy</keyword>
</DOC>